

BVMedReport № 05/16

May 2016
Circulation: 2,200

Dr. Lugan Re-Elected as BVMed Chairman

Berlin. **Dr. Meinrad Lugan** has been re-elected chairman of BVMed for two more years. He became chairman in April 2007. **Christiane Doering**, GHD, and **Steven Anderson**, Paul Hartmann, were elected vice-chairpersons of the board.

DRG Institute Wants to Restructure the System

Cologne. The German National Institute for Remuneration in Hospitals, InEK, has presented a proposal for restructuring the DRG system so that treatments involving high personnel costs will receive higher remuneration, said InEK CEO **Dr. Frank Heimig**. Hospitals with a focus on services with a large share of material costs, e.g. services in the area of heart surgery, would be at the losing end. As far as BVMed's companies are concerned, these plans sound alarming. "These calculations are assessed as incomprehensible by our experts. BVMed therefore intends to demonstrate that the proposal is not adequate and especially denigrates innovative approaches involving medical devices," said BVMed chairman of the board, **Dr. Meinrad Lugan**.

Joint Replacements: The Baby Boomers Are Coming

Berlin. The demographic change will lead to a significant increase in the number of orthopedic and trauma surgery patients until 2050. Experts expect widespread conditions such as osteoarthritis and osteoporosis to increase by 18 and 25 percent respectively. Hence, the German Society for Orthopedics and Trauma is currently discussing how the increase can be managed while maintaining the standard of care.

Higher State Funding for German Healthcare Pool

Berlin. The federal subsidy for the healthcare pool will rise to 14.5 billion euros in 2017. In order to consolidate the federal budget, the amount was reduced to 10.5 billion euros in 2014.

Follow us on Twitter

for the latest medtech news:
www.twitter.com/bvmed

German Medtech Market Grows by 11 Percent

Berlin. Based on official economic statistics, the total sales of the manufacturing medtech companies in Germany grew by 11.6 percent to 28.4 billion euros in 2015. Domestic sales increased by almost 13 percent to 9.2 billion euros. Export sales increased by 11 percent to 19.2 billion euros in 2015. This result is significantly above earlier expectations. The strong growth in 2015 is explained by catch-up effects in the German market, the weak euro exchange rate, low crude oil prices, and increased demand in emerging markets.

Due to high development costs and the further increasing complexity of regulatory requirements on the one side and cost-cutting measures of third-party payers in Germany and other countries on the other side, however, the income situation of many companies is remaining tense. Due to the diversity of the medical device industry with products ranging from consumables to large imaging diagnostic devices, the situation is also highly differentiated, depending on the respective product area.

More at www.medinsight.de.

Benefit Assessment: First Proceedings in Autumn


Berlin. In autumn 2016 the Federal Joint Committee, G-BA, will start implementing the benefit assessment proceedings for new examination and treatment methods involving medical technologies of high risk categories. Throughout the legislative process, the medtech industry successfully advocated that the new regulation would require benefit assessment procedures only for methods comprising a new theoretical scientific concept, or for those of a particularly invasive nature when applied. According to the now effective regulation put forth by the Health Ministry

and the amended G-BA procedural rules, it is expected that gradual innovations will not be affected. Therefore, only few innovative methods will require the G-BA committee to order scientific studies to be conducted.

The medtech companies organized in BVMed would like to see a neutral institution develop guidelines for the methodology of benefit assessment of medical technologies. These guidelines should take better account of the particular nature of medical devices.

More at www.medinsight.de.

MedInsight Germany: Latest News on Europe's Biggest Market!



MedInform has published a new issue of **MedInsight Germany**, a background report authored by the German medtech experts **Joachim M. Schmitt** and **Manfred Beeres** in cooperation with Advamed. **MedInsight** gives the latest news on Europe's biggest medtech market.

Topics of the new issue are e. g.: Benefit Assessment: First Proceedings in Autumn; German Medtech Market Grows by 11 Percent; DRG Institute Wants to Restructure the System; Joint Replacements: The Baby

Boomers Are Coming; Higher State Funding for German Healthcare Pool; Courts Sentence G-BA Committee to More Transparency; Medical Technologies Leading in Patient Applications; Hospitals Demand Funding Program for IT Security.

Advamed, Eucomed and BVMed member companies receive "MedInsight Germany" at a discounted subscription price of € 600 per year (10 issues). The normal subscription fee is € 1,200 per year. You can order a free trial copy of **MedInsight** at: www.medinsight.de